Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cambrex Reports Third Quarter 2010 Results


      News provided by

      Cambrex Corporation

      Nov 03, 2010, 04:12 ET

      Share this article

      Share this article


      EAST RUTHERFORD, N.J., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) reports third quarter results for the period ended September 30, 2010.

      Highlights

      • Reported sales decreased by 14.6%, and excluding the impact of foreign currency, sales decreased 11.5% compared to third quarter 2009.  
      • Adjusted EBITDA was $8.5 million in the third quarter 2010 compared to $11.0 million in the same quarter last year.
      • Debt, net of cash was $71.4 million at the end of third quarter 2010, a decrease of $5.5 million during the quarter including a positive $2.5 million impact of currency on foreign cash balances.
      • Acquired a 51% stake in Zenara Pharma, a Hyderabad, India based pharmaceutical company focused on the formulation of final dosage form products, for $20 million on November 2, 2010.
      • Narrowed the range of 2010 full year guidance for sales, excluding the impact of foreign currency, to a decline of between 3% and 5%, and Adjusted EBITDA to $41 to $44 million.

      Basis of Reporting

      The Company has provided a reconciliation from adjusted amounts to GAAP amounts at the end of this press release.  Management believes that the adjusted amounts provide a more meaningful representation of the Company's operating results for the periods presented due to the magnitude and nature of certain expenses recorded.

      Third Quarter 2010 Operating Results – Continuing Operations

      Third quarter 2010 sales of $49.4 million were 14.6% lower than the third quarter 2009.  Excluding a 3.1% unfavorable impact of foreign exchange, reflecting a stronger U.S. dollar, sales decreased 11.5%.  The decrease is primarily due to the timing of orders for certain products, the effects of a supply chain disruption at a customer's facility, a negotiated contract extension for certain drug delivery products resulting in lower volumes and pricing, and lower custom development and controlled substances shipments.  These decreases were partially offset by higher sales volume of generic active pharmaceutical ingredients ("APIs").

      Third quarter 2010 Gross Margin decreased to 28.6%, but was flat compared to 29.3% in the third quarter 2009 after excluding the impact of foreign currency.  Gross margins were positively impacted by lower production costs, offset by lower pricing.  

      Selling, General and Administrative Expenses in the third quarter 2010 were $7.9 million compared to $9.3 million in the same period last year.  The decrease is a result of lower legal fees and insurance premiums.

      Research and Development ("R&D") Expenses increased to $3.1 million in the third quarter 2010 from $2.0 million in the third quarter 2009 primarily due to the March 2010 acquisition of IEP, reduced utilization of certain R&D personnel on revenue-generating custom development projects resulting in these costs being expensed rather than absorbed into cost of sales or inventory and the development of new products and technology platforms.

      Restructuring Expenses totaling $1.2 million, in the third quarter 2010, include certain one-time employee benefits related to cost reduction activities at a manufacturing site.

      Merger and Acquisition Expenses totaling $0.7 million in the third quarter 2010 include costs related to the acquisition of a 51% equity stake in Zenara Pharma.  

      As a result of the above items, Operating Profit decreased to $1.3 million in the third quarter 2010 from $5.6 million in the third quarter 2009.  Adjusted Operating Profit was $3.2 million compared to $5.6 million for the third quarter last year.  The decrease in Adjusted Operating Profit was driven primarily by lower gross profits described above.

      The Provision for Income Taxes totaled $1.3 million in the third quarter 2010.  The Company's effective tax rate has been and is expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits where there has been a recent history of losses, primarily in the U.S.

      Net Loss for the third quarter 2010 was $1.5 million or $0.05 per share compared to Net Income of $3.0 million or $0.10 per share in the third quarter 2009.  

      Capital expenditures and depreciation for the third quarter 2010 were $3.5 million and $5.3 million compared to $3.3 million and $5.4 million in the third quarter 2009, respectively.

      Steven M. Klosk, President and Chief Executive Officer, said, "Third quarter results primarily reflect the impact of the timing of shipments on our business.  We currently expect much stronger fourth quarter volumes for our larger APIs, but lower revenue expectations for our custom development business, where we provide products and services for clinical phase projects, led us to lower the high end of our sales and profit guidance accordingly.  We continue to be encouraged by the increasing number of requests for proposals for clinical development projects, and the higher percentage of later stage projects on which we are bidding.  Generic order levels continue to be much stronger than prior year and we expect our controlled substances business to show solid growth for the full year.  As part of our ongoing efforts to reduce costs within our business, we restructured one of our manufacturing sites during the third quarter, resulting in a charge for the associated reduction in workforce.

      "As we announced Tuesday, we acquired a 51% stake in Zenara Pharma, a Hyderabad, India based pharmaceutical company focused on the formulation of final dosage form products.  We are very excited about the growth opportunities that this investment will bring to Cambrex.  The integration of Cambrex's API and drug delivery business with Zenara's formulation and finished dosage capabilities will enable us to provide greater value to our pharmaceutical customers.  The combination of our two businesses gives Cambrex a leading position within the nicotine replacement therapy market, supplying both APIs and finished dosage form products.  The Cambrex Zenara technology and cost position will enable us to effectively provide smoking cessation products to our customers for new, potentially large emerging markets.  This investment also gives us a foothold in the growing Indian pharmaceutical market and will allow us to expand our access to new product categories, geographies and customers."

      Guidance – Continuing Operations

      The Company currently expects that sales for 2010, excluding the impact of foreign currency, will be between a decline of 3% and 5% versus 2009, and that full year 2010 Adjusted EBITDA will be between $41 and $44 million.

      For 2010, capital expenditures are expected to be approximately $12 to $14 million and depreciation is expected to be $21 to $22 million.

      The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the third quarter 2010 Form 10-Q is filed with the SEC.

      Conference Call and Webcast

      The Conference Call to discuss third quarter 2010 results will begin at 8:30 a.m. Eastern Time on Thursday, November 4, 2010 and last approximately 45 minutes.  Those wishing to participate should call 1-800-768-6569 for domestic and +1-785-830-7992 for international.  Please use the pass code 2045587 and call approximately 10 minutes prior to start time.  A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com and can be accessed for 30 days following the conference call.  A telephone replay of the conference call will be available through Thursday, November 11, 2010 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 2045587 to access the replay.  

      Forward Looking Statements

      This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under The Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities.  These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions in connection with any discussion of future financial and operating performance.  Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout the Company's public filings.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, the Company's ability to satisfy the continued listing standards of the New York Stock Exchange, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its facilities or products and other factors described under the caption "Risk Factors That May Affect Future Results" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009.  Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.  New factors emerge from time to time and it is not possible for the Company to predict which will arise.  In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

      For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2009 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  

      About Cambrex

      Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.  

      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Quarters Ended September 30, 2010 and 2009

      (in thousands)













      2010


      2009





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      49,356


      100.0%


      $

      57,802


      100.0%

          Allowances and Rebates


      492


      1.0%



      285


      0.5%

      Net Sales


      48,864


      99.0%



      57,517


      99.5%











          Other Revenues


      (1,090)


      -2.2%



      (1,147)


      -2.0%











      Net Revenues


      47,774


      96.8%



      56,370


      97.5%











          Cost of Goods Sold


      33,664


      68.2%



      39,422


      68.2%











      Gross Profit


      14,110


      28.6%



      16,948


      29.3%











      Operating Expenses










          Selling, General and Administrative Expenses


      7,879


      16.0%



      9,295


      16.1%

          Research and Development Expenses


      3,080


      6.2%



      2,026


      3.5%

          Restructuring Expenses


      1,187


      2.5%



      -


      0.0%

          Merger and Acquisition Expenses


      711


      1.4%



      -


      0.0%

      Total Operating Expenses


      12,857


      26.1%



      11,321


      19.6%











      Operating Profit


      1,253


      2.5%



      5,627


      9.7%











      Other Expenses/(Income):










          Interest Expense, net


      1,233


      2.5%



      1,111


      1.9%

          Other Expense/(Income), net


      52


      0.1%



      (31)


      -0.1%











      (Loss)/Income Before Income Taxes


      (32)


      -0.1%



      4,547


      7.9%











          Provision for Income Taxes


      1,252


      2.5%



      1,584


      2.8%











      (Loss)/Income from Continuing Operations

      $

      (1,284)


      -2.6%


      $

      2,963


      5.1%











      Loss from Discontinued Operations


      (170)


      -0.3%



      -


      0.0%











      Net (Loss)/Income

      $

      (1,454)


      -2.9%


      $

      2,963


      5.1%











      Basic (Loss)/Earnings per Share of Common Stock:










        (Loss)/Income from Continuing Operations

      $

      (0.04)




      $

      0.10



        Loss from Discontinued Operations

      $

      (0.01)




      $

      -



       Net (Loss)/Income

      $

      (0.05)




      $

      0.10













      Diluted (Loss)/Earnings per Share of Common Stock:










        (Loss)/Income from Continuing Operations

      $

      (0.04)




      $

      0.10



        Loss from Discontinued Operations

      $

      (0.01)




      $

      -



       Net (Loss)/Income

      $

      (0.05)




      $

      0.10













      Weighted Average Shares Outstanding










          Basic


      29,373





      29,253



          Diluted


      29,373





      29,303





      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Nine Months Ended September 30, 2010 and 2009

      (in thousands)












      2010


      2009





      % of




      % of



      Amount


      Sales


      Amount


      Sales










      Gross Sales

      $

      162,914


      100.0%

      $

      177,568


      100.0%

          Allowances and Rebates


      1,204


      0.7%


      623


      0.4%

      Net Sales


      161,710


      99.3%


      176,945


      99.6%










          Other Revenues


      374


      0.2%


      (262)


      -0.1%










      Net Revenues


      162,084


      99.5%


      176,683


      99.5%










          Cost of Goods Sold


      115,548


      70.9%


      120,919


      68.1%










      Gross Profit


      46,536


      28.6%


      55,764


      31.4%










      Operating Expenses









          Selling, General and Administrative Expenses


      24,784


      15.2%


      26,889


      15.2%

          Research and Development Expenses


      7,906


      4.9%


      5,924


      3.3%

          Restructuring Expenses


      1,187


      0.7%


      -


      0.0%

          Merger and Acquisition Expenses


      786


      0.5%


      -


      0.0%

      Total Operating Expenses


      34,663


      21.3%


      32,813


      18.5%










      Operating Profit


      11,873


      7.3%


      22,951


      12.9%










      Other Expenses/(Income):









          Interest Expense, net


      3,602


      2.2%


      3,410


      1.9%

          Other Expense/(Income), net


      69


      0.1%


      (139)


      -0.1%










      Income Before Income Taxes


      8,202


      5.0%


      19,680


      11.1%










          Provision for Income Taxes


      4,137


      2.5%


      6,520


      3.7%










      Income from Continuing Operations

      $

      4,065


      2.5%

      $

      13,160


      7.4%










      Income from Discontinued Operations


      935


      0.6%


      -


      0.0%










      Net Income

      $

      5,000


      3.1%

      $

      13,160


      7.4%










      Basic Earnings per Share of Common Stock:









        Income from Continuing Operations

      $

      0.14



      $

      0.45



        Income from Discontinued Operations

      $

      0.03



      $

      -



       Net Income

      $

      0.17



      $

      0.45












      Diluted Earnings per Share of Common Stock:









        Income from Continuing Operations

      $

      0.14



      $

      0.45



        Income from Discontinued Operations

      $

      0.03



      $

      -



       Net Income

      $

      0.17



      $

      0.45












      Weighted Average Shares Outstanding









          Basic


      29,341




      29,225



          Diluted


      29,443




      29,249





      CAMBREX CORPORATION

      Reconciliation of GAAP to non-GAAP Results

      For the Quarters and Nine Months Ended September 30, 2010 and 2009

      (in thousands)








      Third Quarter 2010


      Third Quarter 2009







      Operating Profit, as Reported

      $

      1,253


      $

      5,627







      Restructuring Expenses*


      1,187



      -







      Merger and Acquisition Expenses**


      711



      -







      Adjusted Operating Profit


      3,151



      5,627







      Depreciation and Amortization


      5,388



      5,359







      Adjusted EBITDA

      $

      8,539


      $

      10,986
















      Nine Months 2010


      Nine Months 2009







      Operating Profit, as Reported

      $

      11,873


      $

      22,951







      Restructuring Expenses*


      1,187



      -







      Merger and Acquisition Expenses**


      786



      -







      Adjusted Operating Profit


      13,846



      22,951







      Depreciation and Amortization


      15,997



      14,774







      Adjusted EBITDA

      $

      29,843


      $

      37,725









      *  During the third quarter 2010, the Company incurred expenses related to certain one-time employee benefits relating to a plan to restructure its operations at a manufacturing site.  These costs are identified within the 2010 income statement and have been excluded from the calculation of certain profit measurements, including Adjusted EBITDA for 2010.  







      **  During 2010, the Company incurred Merger and Acquisition Expenses pursuant to the acquisition of a 51% equity stake in Zenara Pharma.  These costs are identified within the 2010 income statement and have been excluded from the calculation of certain profit measurements, including Adjusted EBITDA for 2010.  



      CAMBREX CORPORATION

      Consolidated Balance Sheets

      As of September 30, 2010 and December 31, 2009

      (in thousands)









      September 30,



      December 31,

      Assets


      2010



      2009







      Cash and Cash Equivalents

      $

      42,996


      $

      52,365

      Trade Receivables, net


      30,989



      32,025

      Inventories, net


      66,288



      58,369

      Prepaid Expenses and Other Current Assets


      8,497



      6,654

       Total Current Assets


      148,770



      149,413







      Property, Plant and Equipment, net


      153,614



      161,149

      Goodwill and Intangibles, net


      43,199



      36,360

      Other Non-Current Assets


      4,095



      4,593







       Total Assets

      $

      349,678


      $

      351,515







      Liabilities and Stockholders' Equity












      Accounts Payable

      $

      18,123


      $

      17,038

      Accrued Expenses and Other Current Liabilities


      36,910



      38,013

       Total Current Liabilities


      55,033



      55,051







      Long-term Debt


      114,400



      120,800

      Deferred Income Taxes


      18,388



      17,305

      Accrued Pension and Postretirement Benefits


      41,506



      40,963

      Other Non-Current Liabilities


      13,102



      14,126







       Total Liabilities

      $

      242,429


      $

      248,245







       Stockholders’ Equity

      $

      107,249


      $

      103,270







       Total Liabilities and Stockholders’ Equity

      $

      349,678


      $

      351,515



      SOURCE Cambrex Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.